Current and historical daily PE Ratio for Dynavax Technologies Corp (
) from 2004 to Apr 27 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Dynavax Technologies stock (DVAX) PE ratio as of Apr 27 2024 is 0.
More Details
Dynavax Technologies Corp (DVAX) PE Ratio (TTM) Chart
Dynavax Technologies Corp (DVAX) PE Ratio (TTM) Historical Data
View and export this data going back to 2004. Start your Free Trial
Total 1221
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Dynavax Technologies PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-27 | At Loss | 2024-02-26 | At Loss |
| 2024-04-26 | At Loss | 2024-02-23 | At Loss |
| 2024-04-25 | At Loss | 2024-02-22 | At Loss |
| 2024-04-24 | At Loss | 2024-02-21 | At Loss |
| 2024-04-23 | At Loss | 2024-02-20 | At Loss |
| 2024-04-22 | At Loss | 2024-02-19 | At Loss |
| 2024-04-19 | At Loss | 2024-02-16 | At Loss |
| 2024-04-18 | At Loss | 2024-02-15 | At Loss |
| 2024-04-17 | At Loss | 2024-02-14 | At Loss |
| 2024-04-16 | At Loss | 2024-02-13 | At Loss |
| 2024-04-15 | At Loss | 2024-02-12 | At Loss |
| 2024-04-12 | At Loss | 2024-02-09 | At Loss |
| 2024-04-11 | At Loss | 2024-02-08 | At Loss |
| 2024-04-10 | At Loss | 2024-02-07 | At Loss |
| 2024-04-09 | At Loss | 2024-02-06 | At Loss |
| 2024-04-08 | At Loss | 2024-02-05 | At Loss |
| 2024-04-05 | At Loss | 2024-02-02 | At Loss |
| 2024-04-04 | At Loss | 2024-02-01 | At Loss |
| 2024-04-03 | At Loss | 2024-01-31 | At Loss |
| 2024-04-02 | At Loss | 2024-01-30 | At Loss |
| 2024-04-01 | At Loss | 2024-01-29 | At Loss |
| 2024-03-29 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
| 2024-03-21 | At Loss | 2024-01-18 | At Loss |
| 2024-03-20 | At Loss | 2024-01-17 | At Loss |
| 2024-03-19 | At Loss | 2024-01-16 | At Loss |
| 2024-03-18 | At Loss | 2024-01-15 | At Loss |
| 2024-03-15 | At Loss | 2024-01-12 | At Loss |
| 2024-03-14 | At Loss | 2024-01-11 | At Loss |
| 2024-03-13 | At Loss | 2024-01-10 | At Loss |
| 2024-03-12 | At Loss | 2024-01-09 | At Loss |
| 2024-03-11 | At Loss | 2024-01-08 | At Loss |
| 2024-03-08 | At Loss | 2024-01-05 | At Loss |
| 2024-03-07 | At Loss | 2024-01-04 | At Loss |
| 2024-03-06 | At Loss | 2024-01-03 | At Loss |
| 2024-03-05 | At Loss | 2024-01-02 | At Loss |
| 2024-03-04 | At Loss | 2024-01-01 | At Loss |
| 2024-03-01 | At Loss | 2023-12-29 | At Loss |
| 2024-02-29 | At Loss | 2023-12-28 | At Loss |
| 2024-02-28 | At Loss | 2023-12-27 | 36.2 |
| 2024-02-27 | At Loss | 2023-12-26 | 36.0 |
Dynavax Technologies Corp (DVAX) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Dynavax Technologies Corp
NAICS : 325412
SIC : 2834
ISIN : US2681582019
Share Class Description:
DVAX: Ordinary SharesDescription
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers